Intrathecal ziconotide and opioid combination therapy for noncancer pain: An observational study

Pain Physician

Volumn 12, Issue 4, 2009, Pages

  Deer, Timothy ^a   Kim, Christopher ^a   Bowman, Richard ^a   Tolentino, Diana ^a   Stewart, C ^a   Tolentino, Wilfrido ^a  

^a Center for Pain Relief Inc   (United States)

Author keywords

Chronic pain; Combination therapy; Intrathecal; Nonopioid analgesic; Opioids; Ziconotide

Indexed keywords

BACLOFEN; BUPIVACAINE; CLONIDINE; FENTANYL; HYDROMORPHONE; MORPHINE; OMEGA CONOTOXIN MVIIA; OPIATE; SUFENTANIL; ANALGESIC AGENT; NARCOTIC ANALGESIC AGENT; OMEGA CONOTOXIN;

ADULT; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; COMPLEX REGIONAL PAIN SYNDROME; DEPRESSION; DISEASE DURATION; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LAMINECTOMY; LOW BACK PAIN; MALE; NEURALGIA; NEURITIS; OBSERVATIONAL STUDY; PAIN; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; RADICULITIS; SPRAIN; THORAX PAIN; VERTEBRAL CANAL STENOSIS; VISUAL ANALOG SCALE; CLASSIFICATION; CLINICAL TRIAL; DRUG COMBINATION; INTRASPINAL DRUG ADMINISTRATION; METHODOLOGY; OBSERVATION; PAIN ASSESSMENT; RETROSPECTIVE STUDY;

ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, SPINAL; MALE; OBSERVATION; OMEGA-CONOTOXINS; PAIN; PAIN MEASUREMENT; RETROSPECTIVE STUDIES;

EID: 70350441859     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Roper Starch Worldwide Inc. Chronic pain in America: Roadblocks to relief. American Pain Society Web site. www.ampainsoc.org/links/roadblocks/. Published January 1999. Accessed March 11, 2009.
2. Becker N, Bondegaard Thomsen A, Olsen AK, Sjøgren P, Bech P, Eriksen J. Pain epidemiology and health related quality of life in chronic non-malignant pain patients referred to a Danish multidisciplinary pain center. Pain 1997; 73:393-400. (Pubitemid 28021844)
3. Prager JP. Neuraxial medication delivery: The development and maturity of a concept for treating chronic pain of spinal origin. Spine 2002; 27:2593-2606.
4. Miljanich GP. Ziconotide: Neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem 2004; 11:3029-3040.
5. Wang YX, Bezprozvannaya S, Bowersox SS, Nadasdi L, Miljanich G, Mezo G, Silva D, Tarczy-Hornoch K, Luther RR. Peripheral versus central potencies of N-type voltage-sensitive calcium channel blockers. Naunyn Schmiedebergs Arch Pharmacol 1998; 357:159-168. (Pubitemid 28085516)
6. Wang YX, Gao D, Pettus M, Phillips C, Bowersox SS. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats. Pain 2000; 84:271-281. (Pubitemid 30074229)
7. Pirec V, Laurito CE, Lu Y, Yeomans DC. The combined effects of N-type calcium channel blockers and morphine on A delta versus C fiber mediated nociception. Anesth Analg 2001; 92:239-243. (Pubitemid 32039212)
8. Sarhill N, Walsh D, Nelson KA. Hydromorphone: Pharmacology and clinical applications in cancer patients. Support Care Cancer 2001; 9:84-96. (Pubitemid 32246454)
9. Soldo BL, Moises HC. mu-Opioid receptor activation decreases N-type Ca2+ current in magnocellular neurons of the rat basal forebrain. Brain Res 1997; 758:118-126.
10. Waara-Wolleat KL, Hildebrand KR, Stewart GR. A review of intrathecal fentanyl and sufentanil for the treatment of chronic pain. Pain Med 2006; 7:251-259. (Pubitemid 43676671)
11. Deer T, Krames ES, Hassenbusch SJ, Burton A, Caraway D, DuPen S, Eisenach J, Erdek M, Grigsby E, Kim P, Levy R, McDowell G, Mekhail N, Panchal S, Prager J, Rauck R, Saulino M, Sitzman T, Staats P, Stanton-Hicks M, Stearns L, Willis KD, Witt W, Follett K, Huntoon M, Liem L, Rathmell J, Wallace M, Buchser E, Cousins M, Ver Donck A. Polyanalgesic Consensus Conference 2007: Recommendations for the management of pain by intrathecal (intraspinal) drug delivery: Report of an interdisciplinary expert panel. Neuromodulation 2007; 10:300-328.
12. Wallace MS, Kosek PS, Staats P, Fisher R, Schultz DM, Leong M. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: Addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med 2008; 9:271-281.
13. Webster LR, Fakata KL, Charapata S, Fisher R, MineHart M. Open-label, multicenter study of combined intrathecal morphine and ziconotide: Addition of morphine in patients receiving ziconotide for severe chronic pain. Pain Med 2008; 9:282-290.
14. Rauck RL, Wallace MS, Leong MS, MineHart M, Webster LR, Charapata SG, Abraham JE, Buffington DE, Ellis D, Kartzinel R. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage 2006; 31:393-406.
15. Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, Fisher R, Bryce DA, Mangieri EA, Luther RR, Mayo M, McGuire D, Ellis D. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: A randomized controlled trial. JAMA 2004; 291:63-70.
16. Wallace MS, Charapata SG, Fisher R, Byas-Smith M, Staats PS, Mayo M, McGuire D, Ellis D. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: A randomized, double-blind, placebo-controlled clinical trial. Neuromodulation 2006; 9:75-86.
17. Kumar K, Kelly M, Pirlot T. Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: Long-term benefits and efficacy. Surg Neurol 2001; 55:79-88. (Pubitemid 32297679)
18. Naumann C, Erdine S, Koulousakis A, Van Buyten JP, Schuchard M. Drug adverse events and system complications of intrathecal opioid delivery for pain: origins, detection, manifestations, and management. Neuromodulation 1999; 2:92-107. (Pubitemid 29268517)
19. Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, Buchser E, Catalá E, Bryce DA, Coyne PJ, Pool GE. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: Impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002; 20:4040-4049.
20. Eastman MJ, Johnson SP. Ziconotide combination intrathecal therapy. Practical Pain Manage 2007; 7:88-92.
21. PRIALT® [package insert]. San Diego, CA: Elan Pharmaceuticals, Inc.; 2007.
22. Shields D, Montenegro R, Ragusa M. Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration. Neuromodulation 2005; 8:257-263. (Pubitemid 43942736)
23. Shields DE, Aclan J, Szatkowski A. Chemical stability of admixtures combining ziconotide with fentanyl or sufentanil during simulated intrathecal administration. Int J Pharm Compounding 2008; 12:463-466.
24. Shields DE, Aclan J, Szatkowski A. Chemical stability of admixtures containing ziconotide 25 mcg/mL and morphine sulfate 10 mg/mL or 20 mg/mL during simulated intrathecal administration. Int J Pharm Compounding 2008; 12:553-557.